Cargando…

Zygomycosis in Immunocompromised non-Haematological Patients

Zygomycoses caused by fungi of the mucorales order (mucormycoses) are emerging fungal diseases with a high fatality rate. The most important risk factors include neutropenia or functional neutropenia, diabetic ketoacidosis, iron overload, major trauma, prolonged use of corticosteroids, illicit intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrikkos, George, Drogari-Apiranthitou, Miranda
Formato: Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103240/
https://www.ncbi.nlm.nih.gov/pubmed/21625316
http://dx.doi.org/10.4084/MJHID.2011.012
_version_ 1782204501190508544
author Petrikkos, George
Drogari-Apiranthitou, Miranda
author_facet Petrikkos, George
Drogari-Apiranthitou, Miranda
author_sort Petrikkos, George
collection PubMed
description Zygomycoses caused by fungi of the mucorales order (mucormycoses) are emerging fungal diseases with a high fatality rate. The most important risk factors include neutropenia or functional neutropenia, diabetic ketoacidosis, iron overload, major trauma, prolonged use of corticosteroids, illicit intravenous drug (ID) use, neonatal prematurity, malnourishment, and maybe a previous exposure to antifungal agents with no activity against zygomycetes, such as voriconazole and echinocandins. A high index of suspicion is crucial for the diagnosis, as prompt and appropriate management can considerably reduce morbidity and mortality. Suspicion index can be increased through recognition of the differential patterns of clinical presentation. In the non- haematological immunocompromised patients, mucormycosis can manifest in various clinical forms, depending on the underlying condition: mostly as rhino-orbital or rhino-cerebral in diabetes patients, pulmonary infection in patients with malignancy or solid organ transplantation, disseminated infection in iron overloaded or deferoxamine treated patients, cerebral - with no sinus involvement - in ID users, gastrointestinal in premature infants or malnourishment, and cutaneous after direct inoculation in immunocompetent individuals with trauma or burns. Treating a patient’s underlying medical condition and reducing immunosuppression are essential to therapy. Rapid correction of metabolic abnormalities is mandatory in cases such as uncontrolled diabetes, and corticosteroids or other immunosuppressive drugs should be discontinued where feasible. AmphotericinB or its newer and less toxic lipid formulations are the drugs of choice regarding antifungal chemotherapy, while extensive surgical debridement is essential to reduce infected and necrotic tissue. A high number of cases could be prevented through measures including diabetes control programmes and proper pre- and post-surgical hygiene.
format Text
id pubmed-3103240
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Università Cattolica del Sacro Cuore
record_format MEDLINE/PubMed
spelling pubmed-31032402011-05-27 Zygomycosis in Immunocompromised non-Haematological Patients Petrikkos, George Drogari-Apiranthitou, Miranda Mediterr J Hematol Infect Dis Review Articles Zygomycoses caused by fungi of the mucorales order (mucormycoses) are emerging fungal diseases with a high fatality rate. The most important risk factors include neutropenia or functional neutropenia, diabetic ketoacidosis, iron overload, major trauma, prolonged use of corticosteroids, illicit intravenous drug (ID) use, neonatal prematurity, malnourishment, and maybe a previous exposure to antifungal agents with no activity against zygomycetes, such as voriconazole and echinocandins. A high index of suspicion is crucial for the diagnosis, as prompt and appropriate management can considerably reduce morbidity and mortality. Suspicion index can be increased through recognition of the differential patterns of clinical presentation. In the non- haematological immunocompromised patients, mucormycosis can manifest in various clinical forms, depending on the underlying condition: mostly as rhino-orbital or rhino-cerebral in diabetes patients, pulmonary infection in patients with malignancy or solid organ transplantation, disseminated infection in iron overloaded or deferoxamine treated patients, cerebral - with no sinus involvement - in ID users, gastrointestinal in premature infants or malnourishment, and cutaneous after direct inoculation in immunocompetent individuals with trauma or burns. Treating a patient’s underlying medical condition and reducing immunosuppression are essential to therapy. Rapid correction of metabolic abnormalities is mandatory in cases such as uncontrolled diabetes, and corticosteroids or other immunosuppressive drugs should be discontinued where feasible. AmphotericinB or its newer and less toxic lipid formulations are the drugs of choice regarding antifungal chemotherapy, while extensive surgical debridement is essential to reduce infected and necrotic tissue. A high number of cases could be prevented through measures including diabetes control programmes and proper pre- and post-surgical hygiene. Università Cattolica del Sacro Cuore 2011-03-15 /pmc/articles/PMC3103240/ /pubmed/21625316 http://dx.doi.org/10.4084/MJHID.2011.012 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Petrikkos, George
Drogari-Apiranthitou, Miranda
Zygomycosis in Immunocompromised non-Haematological Patients
title Zygomycosis in Immunocompromised non-Haematological Patients
title_full Zygomycosis in Immunocompromised non-Haematological Patients
title_fullStr Zygomycosis in Immunocompromised non-Haematological Patients
title_full_unstemmed Zygomycosis in Immunocompromised non-Haematological Patients
title_short Zygomycosis in Immunocompromised non-Haematological Patients
title_sort zygomycosis in immunocompromised non-haematological patients
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103240/
https://www.ncbi.nlm.nih.gov/pubmed/21625316
http://dx.doi.org/10.4084/MJHID.2011.012
work_keys_str_mv AT petrikkosgeorge zygomycosisinimmunocompromisednonhaematologicalpatients
AT drogariapiranthitoumiranda zygomycosisinimmunocompromisednonhaematologicalpatients